U.S. Atherectomy Devices Market Increasing Demand And Forecast To 2025

Posted by Neha Bora on March 2nd, 2020

San Francisco, 2 March 2020: The Report U.S. Atherectomy Devices Market Size, Share & Trends Analysis Report By Type (Laser, Directional, Rotational, Orbital), By End Use (Office-based Labs, Out-patient Facility, In-patient Facility), And Segment Forecasts, 2019 – 2025

The U.S. atherectomy devices market size is expected to reach USD 626.1 million by 2025 expanding at a CAGR of 6.6%, according to a new report by Grand View Research, Inc. The regional market is expected to witness lucrative growth due to the rising prevalence of target diseases and preference for endovascular procedures. Moreover, rising demand for minimally invasive procedure will boost the market growth. Such procedures are less painful and allow quicker recovery than invasive procedures.

Other advantages, such as higher patient satisfaction owing to fewer incision wounds, few post-surgical complications, and low mortality rates, are also driving the atherectomy devices market growth. Technological advancements allowing early diagnosis are also likely to augment the market growth in the near future. For instance, in January 2017, Medtronic received CE mark approval for HawkOne directional atherectomy system for treating patients suffering from Peripheral Artery Disease (PAD).

Access Research Report of U.S. Atherectomy Devices Market @ www.grandviewresearch.com/industry-analysis/us-atherectomy-devices-market

Further key findings from the study suggest:

• Adoption of atherectomy increased sharply in the past due to increased reimbursement for the procedure. According to Elsevier Inc., there was a rise in atherectomy volume for Medicare beneficiaries to 76% in 2011–2015
• Directional atherectomy devices accounted for the largest share of the market in 2017 as the device exhibited 95% successful removal of lesions and 94% of patients did not exhibit adverse effects
• Office-Based Labs (OBLs) is anticipated to be the fastest-growing segment in the forecast period due to a greater number of Peripheral Vascular Interventional (PVI) procedures being performed in this setting
• In addition, lesser number of complications and follow-up procedures lowers the cost and increases the adoption of new technologies delivering better health outcomes, which is anticipated to propel the market growth in the coming years
• Several ongoing trials and their positive results facilitate penetration of novel technologies. For instance, in March 2017, Cardiovascular Systems, Inc. enrolled for its latest clinical trial, ECLIPSE, which was perceived to be the largest trial conducted to study coronary atherectomy
• Some of the key companies are Spectranetics Corp.; Boston Scientific Corp.; Cardinal Health, Inc.; Straub Medical AG; Terumo Medical Corp.; Cardiovascular Systems, Inc.; Medtronic PLC; Avinger, Inc.; ST. JUDE MEDICAL, Inc.